Greenline Partners LLC Sells 5,342 Shares of Pfizer Inc. (PFE)

Greenline Partners LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.2% during the 2nd quarter, Holdings Channel reports. The firm owned 236,461 shares of the biopharmaceutical company’s stock after selling 5,342 shares during the quarter. Pfizer comprises approximately 2.8% of Greenline Partners LLC’s holdings, making the stock its 15th biggest position. Greenline Partners LLC’s holdings in Pfizer were worth $8,581,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in PFE. Naples Global Advisors LLC increased its position in shares of Pfizer by 5.4% during the second quarter. Naples Global Advisors LLC now owns 33,695 shares of the biopharmaceutical company’s stock valued at $1,222,000 after buying an additional 1,712 shares during the period. Steward Partners Investment Advisory LLC increased its position in shares of Pfizer by 25.1% during the second quarter. Steward Partners Investment Advisory LLC now owns 285,325 shares of the biopharmaceutical company’s stock valued at $10,352,000 after buying an additional 57,176 shares during the period. Destination Wealth Management increased its position in shares of Pfizer by 962,667.3% during the second quarter. Destination Wealth Management now owns 500,639 shares of the biopharmaceutical company’s stock valued at $18,163,000 after buying an additional 500,587 shares during the period. Gagnon Securities LLC increased its position in shares of Pfizer by 61.1% during the first quarter. Gagnon Securities LLC now owns 14,708 shares of the biopharmaceutical company’s stock valued at $522,000 after buying an additional 5,581 shares during the period. Finally, Pennsylvania Trust Co increased its position in shares of Pfizer by 10.9% during the second quarter. Pennsylvania Trust Co now owns 681,255 shares of the biopharmaceutical company’s stock valued at $28,127,000 after buying an additional 67,151 shares during the period. 69.01% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages have recently weighed in on PFE. Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, July 15th. Goldman Sachs Group reiterated a “neutral” rating and set a $45.00 price target on shares of Pfizer in a research report on Tuesday, October 30th. Societe Generale set a $43.00 price target on Pfizer and gave the company a “hold” rating in a research report on Thursday. Credit Suisse Group reiterated a “neutral” rating and set a $40.00 price target on shares of Pfizer in a research report on Tuesday, October 30th. Finally, BMO Capital Markets reiterated a “buy” rating and set a $42.00 price target on shares of Pfizer in a research report on Thursday, July 19th. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $42.95.

PFE stock opened at $42.93 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $255.56 billion, a P/E ratio of 16.20, a P/E/G ratio of 2.16 and a beta of 0.88. Pfizer Inc. has a 1-year low of $33.20 and a 1-year high of $45.81.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.03. The company had revenue of $13.30 billion for the quarter, compared to analysts’ expectations of $13.53 billion. Pfizer had a net margin of 44.63% and a return on equity of 25.34%. Pfizer’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.67 earnings per share. As a group, sell-side analysts predict that Pfizer Inc. will post 3 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be given a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 3.17%. The ex-dividend date is Thursday, November 8th. Pfizer’s dividend payout ratio (DPR) is 51.32%.

In other Pfizer news, insider Laurie J. Olson sold 10,214 shares of the company’s stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $41.00, for a total value of $418,774.00. Following the completion of the sale, the insider now owns 72,672 shares of the company’s stock, valued at $2,979,552. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Pfizer Inc bought 55,556 shares of the business’s stock in a transaction on Monday, October 15th. The stock was purchased at an average cost of $18.00 per share, with a total value of $1,000,008.00. Following the purchase, the insider now owns 21,976,484 shares of the company’s stock, valued at $395,576,712. The disclosure for this purchase can be found here. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Read More: What are the benefits of a balanced fund?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply